Connect with us

Featured

Premier Health (OTC:PHGRF) (CSE:PHGI) Signs Definitive Agreement for Acquisition of Cloud Practice Inc., a National Medical Software Application Company

Joe Samuel

Published

on

  • Cloud Practice Inc. products include: Juno EMR, a cloud based EMR solution; ClinicAid, a medical billing software; and MyHealthAccess, an online patient portal
  • The Juno EMR system is currently used by 287 clinics, over 3,000 licensed practitioners, 1,500 staff and 2,870,000 registered patients
  • Cloud Practice services over 60 Cannabis Clinics with over 120,000 active patients.
  • ClinicAid processes upwards of $30,000,000 in payments to over 3000 health providers on a monthly basis

VANCOUVER, British Columbia, January 10, 2018 – Premier Health Group Inc. (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry, is pleased to announce, further to its news release dated December 17, 2018, the Company has signed a Definitive Agreement (“the Agreement”) to acquire all of the outstanding securities of Cloud Practice Inc. (“Cloud Practice”).

EXCLUSIVE: Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

Cloud Practice’s founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers. The combined Premier and Cloud Practice ecosystem consists of over 3,000,000 patients.

“We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system,” said Dr. Essam Hamza, CEO of Premier.

Jordan Visco, CEO of Cloud Practice, stated: “We are thrilled to be joining a progressive group such as Premier Health. We are focused on delivering top quality service to Canada’s healthcare industry and we are confident that with Cloud Practice’s offerings combined with the Premier Health teams’ expertise and long-term vision, we can achieve considerable success.”

In consideration for the acquisition of all of the outstanding Cloud Practice securities, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and (v) an aggregate of $3 million payable in common shares of Premier at a deemed price of $0.76 per share.

All shares issued in the transaction are subject to a restricted period of four months and one day. There were no finder’s fees paid in connection with the Transaction.

ON BEHALF OF THE BOARD OF DIRECTORS

“Dr. Essam Hamza, MD”

Chief Executive Officer

 

About Premier Health

 

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are developing innovative health care approaches that combine human skill based expertise with emerging technologies, with the goal of setting the gold standard for services in locations of interest worldwide. Premier Health’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The HealthVue team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.

 

About Cloud Practice

 

Cloud Practice is a cloud-based software solutions company focused on streamlining medical practice throughout Canada. They offer three products including Juno EMR, ClinicAid and MyHealthAccess. Juno EMR, a modified branch of an open-source electronic medical records (EMR) software which was originally released by McMaster University, is hosted in the cloud and can be accessed anywhere, anytime. ClinicAid is Canada’s easiest medical billing software. MyHealthAccess is an online patient portal which puts patients back in control of their health care through connecting with their clinics and booking appointments online.

Cautionary Statements

This news release contains forward-looking statements that are based on Premier Health’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans, completion of its acquisition of Cloud Practice, and the timing thereof, the expected benefits to the Company following the integration of Cloud Practice’s software and the expected implementation of new applications, including the timing thereof, the expect growth to Cloud Practice’s business and the expected synergies resulting from the Company’s acquisition of Cloud Practice. Although Premier Health believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Premier Health undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

FOR ADDITIONAL INFORMATION CONTACT:

Premier Health Group Inc.

www.mypremierhealth.com

Email: investors@mypremierhealth.com

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full disclaimer.

Continue Reading
Click to comment

Biotechnology

StockPrice.com Subscribers WIN BIG!

Jon Phillip

Published

on

stock price WINNING

We owe you a BIG congratulations. The whole point of StockPrice.com is to bring you important information, first. Sure we send emails out every day on top trending articles and news but we also bring periodic reports on certain companies.

Earlier this year we brought you a full report on a company, PharmaCyte Biotech (PMCB).

Since that report, we’ve watched as PharmaCyte evolved into what it has become today: a biotech powerhouse on the verge of presenting its treatment to the FDA!

Stock Price Subscribers Saw The Full PMCB 90%+ Breakout From August – December; Congratulations! Click Here to Read Our Original Report

This is a great thing for subscribers and we’ve got more featured reports coming! How do you get these reports first?


STEP 1: Make Sure Our Email Address Is In Your Whitelist Address Book So Nothing Gets Lost In Spam

STEP 2:Take Out Your Cell Phone And Text “STOCKPRICE” to 63566. Even If You Miss An Email, We Send Out Updates Directly To Your Cell Phone In Real Time

Again, congratulations to everyone and make sure you stay tuned for our next Stock Price Exclusive Report!




Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading

Featured

Stock Price Newsletter – December 12, 2019

Joe Samuel

Published

on

penny stocks news

Are These Biotech Stocks To Buy Or Sell Right Now?

One of the sectors that have proven to be a consistently steady performer in the stock market over the past few years is the biotech sector. Hence, it is not really a surprise that investors are almost always on the lookout for the next big thing among biotech stocks.

Click To Read More


The $40 Billion Dollar Content Gold Rush

Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing… New & Original Content! Massive Demand May Create Huge Opportunity for One Company.

See For Yourself


3 Penny Stocks To Watch Before The End of 2019: One Up 308%

Penny stocks have often proven to be one of the best classes of stocks to invest in if you like high risk. These cheap stocks allow investors to get into the stock market with a small capital account and buy thousands or even millions of shares of stock at a time. Since these low priced stocks tend to move by pennies at a time, that slight change can equate to large percentage moves.

Continue Reading

Continue Reading

Featured

3 Penny Stocks To Watch Before The End of 2019: One Up 308%

Jon Phillip

Published

on

stocks to buy now

Penny stocks have often proven to be one of the best classes of stocks to invest in if you like high risk. These cheap stocks allow investors to get into the stock market with a small capital account and buy thousands or even millions of shares of stock at a time. Since these low priced stocks tend to move by pennies at a time, that slight change can equate to large percentage moves.

That being said, investors need to keep in mind that research is key. That’s in order to discover potentially winning trades in the market. Here is a look at the list of penny stocks that could end up on some watch lists this month.

Penny Stocks To Watch #1: Iterum Therapeutics

stocks to watch Iterum Therapeutics

One of the penny stocks that made a significant move on Tuesday was that of Iterum Therapeutics PLC (ITRM Stock Report) and the move came about after the company made a major announcement. The company announced that the Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial of its product managed to hit the endpoint set by the United States Food and Drug Administration.

The medicine in question is meant for the treatment of complex inter-abdominal infections. The news proved to be a highly positive one for the company and the market thought so as well. ITRM stock rallied by as much as 22% after the news broke and Iterum has emerged as one of the companies that could be tracked for the rest of the week.

Penny Stocks To Watch #2 Technical Communications

stocks to watch Technical Communications Corporation

The other penny stock that went on a massive rally on Tuesday is the Technical Communications Corporation (TCCO Stock Report) stock. The rally came about after the company blew analysts’ estimates out of the water in its third quarter and swung back to profit as well.

After having made losses of $239,000 in the year-ago period, Technical Communications reported profits of $1.03 million and that reflects a remarkable turnaround. The company managed to complete a wide range of overseas contracts and that boosted its earnings. TCCO stock has rallied by as much as 308%.

Penny Stocks To Watch #3 Equillium

stocks to watch Equillium Inc

Lastly, Equillium Inc (EQ Stock Report) has emerged as another penny stock that has recorded impressive gains in recent days. Over the past two weeks, EQ stock has gained as much as 47% and on Wednesday it went up by 10% yet again.

Yesterday, the company announced that its Lupus Nephritis treatment Itolizumab has been granted fast track status by the U.S. FDA and that resulted in a rally in the stock as investors flocked to it pretty quickly. It could be a stock worth watching in the coming days.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com